Please get involved in our new dementia study that aims to enhance early detection, improve prevention, and shape future health policies surrounding dementia. Dementia is a life changing syndrome that is set to affect 1.6 million people in the UK by 2040. GFCT and our research team at Manchester University are determined to advance research around dementia and help change the trajectory of the condition by improving early detection and prevention, which is why we are conducting this new Com...

Graham Fulford and Susan Hart attended the Kings Award for Enterprise Presentation on Friday the 31st January 2025 at Warwick University.  GFCT were honoured to attend this event highlighting the achievements of businesses across Warwickshire and the West Midlands. These awards celebrate excellence in Innovation, Sustainability, Export, and Social Responsibility—showing how businesses are driving meaningful change.As a charity, we were especially inspired by hearing suc...

We are proud to announce that we now have closer working links with Prost8 - a charity dedicated to helping newly diagnosed prostate cancer patients access the best available treatment. GFCT founder, Graham Fulford MBE, said "I was introduced to Paul Sayer, founder of Prost8, at BAUS last year and was immediately impressed by his passion, knowledge and determined approach to helping men get the best treatment.”   Having been diagnosed himself with prostate can...

Expanding Access to HIFU Treatment for Prostate Cancer: GFCT’s Mission A Call for Ethical Investments to Improve Prostate Cancer Treatment Accessibility For over 20 years, GFCT has led the way in advocating for early prostate cancer diagnosis and improved treatment options. Now, in a groundbreaking initiative, we are seeking to raise £1 million to finance the purchase of three High-Intensity Focused Ultrasound (HIFU) machines, ensuring that men outside London have acce...

Prostate Awareness Founder & Recently Diagnosed Prostate Cancer Sufferer Calls Men To Arms  Graham Fulford, MBE, Founder and Trustee of the Warwick based Charity GFCT is calling all men over 40 to consider having a PSA test to check their risk of developing prostate cancer.   Having formed the Charity in 2004 following the late diagnosis of a close friend and relative, both of whom lost their battle with this insidious disease, Graham and the many Groups he works wit...

In collaboration with Manchester University who are undertaking a new research project, we are offering a discounted testing package for those who would like to take part.  For men - £100 - PSA, diabetes, cholesterol, thyroid, kidney function, liver function, vitamin D, iron count and xMOT. For women - £87.50 - diabetes, cholesterol, thyroid, kidney function, liver function, vitamin D, iron count and xMOT.  The discounted price covers the full range of health...

Black men are more likely to be diagnosed with prostate cancer and less likely to receive radical treatment for high-risk cases compared to white men, a new report by the National Prostate Cancer Audit has found.  The National Prostate Cancer Audit (NPCA) State of the Nation Report, published in January 2025, evaluates prostate cancer rates and the care provided to men diagnosed with the disease in England and Wales between 1st Jan 2019 and 31st Dec 2023.  Key ...

A new prostate cancer research update from Practice Update: High Omega-3, Low Omega-6 Fatty Acid Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance - https://www.practiceupdate.com/c/173709/2/1/ The study tested whether a diet high in omega-3s and low in omega-6s, along with fish oil, could slow prostate cancer growth in men with low-risk prostate cancer. Over one year, 100 men were split into two groups: one followed the special diet, and the other ate no...

A new prostate cancer research update from Practice Update: Prebiopsy MRI Oncologically Safe for Suspected Prostate Cancer - https://www.practiceupdate.com/news/48462/2/1This study found that it’s safe for men with suspected prostate cancer to skip a biopsy if their MRI results don’t show any signs of cancer. Researchers monitored these men for three years and found they didn’t have a higher risk of serious prostate cancer compared to those who had a biopsy right...

Great news from The Christie NHS Foundation Trust:The STAMPEDE trial, the world’s largest prostate cancer intervention study with nearly 12,000 participants, has shown that metformin can reduce hormone therapy side effects in advanced prostate cancer treatment.Patients taking metformin alongside standard therapy experienced significantly less weight gain, lower blood sugar levels, and reduced harmful fats compared to those on standard therapy alone.Professor Noel Clarke, a principal i...